Semaglutide
Also known as Ozempic, Wegovy, Rybelsus
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes but now widely used for weight loss. It reduces appetite and slows gastric emptying — producing 15–20% average body weight reduction in clinical trials at the highest doses.
How it works
GLP-1 receptor agonist. Increases insulin secretion, decreases glucagon, slows gastric emptying, and acts centrally on hypothalamus to reduce appetite. Long half-life (~7 days) allows weekly dosing.
Benefits
- 15–20% body weight reduction in clinical trials
- Significant reduction in appetite and cravings
- Improved blood sugar control
- Cardiovascular risk reduction (FDA indication)
- Reduced binge eating behaviors
- Potential neuroprotective effects (emerging research)
Dosing
0.25–2.4 mg · Once weekly
Titration protocol critical — start 0.25mg/week for 4 weeks, increase every 4 weeks to 0.5 → 1.0 → 1.7 → 2.4mg. Max dose 2.4mg/week (Wegovy).
Ranges reflect commonly cited research protocols, not a prescription. Dose with a licensed provider.
Common stacks
Reported side effects
- Nausea (very common, especially early)
- Vomiting
- Diarrhea
- Constipation
- Rare: pancreatitis
- Muscle loss without resistance training
Who it’s for
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Also widely used off-label. Medical supervision strongly recommended.
Track Semaglutide in Helix
Dose reminders, reconstitution math, vial tracking, and AI guidance — free on iOS.
Download free